Aspen Neuroscience, a biotech developing the first autologous neuron replacement for Parkinson’s disease, is seeing double, as investors have flooded the company’s series B with $147.5 million following an initial $70 million round two years ago.
The private neurodegenerative disease biotech’s second funding round was co-led by venture capital firm and Alphabet spin-out GV, LYFE Capital and Revelation Partners. Additional new investors include Newton Investment Management, EDBI, LifeForce Capital, Medical Excellence Capital Partners, Mirae Asset Capital, NS Investment, among others.
